Praxis’ Vormatrigine Shows Promising Seizure Control in Phase II Trial

Praxis Precision Medicines’ oral therapy vormatrigine achieved complete seizure elimination in 22% of patients with focal onset seizures during the last 28 days of an eight-week Phase II RADIANT trial (NCT06908356). Among ~50 participants, median seizure frequency dropped 56.3%, with over half achieving a ≥50% response by week one, sustained throughout treatment. Vormatrigine was well-tolerated.

The drug blocks voltage-gated sodium channels, targeting hyperexcitable neuronal states. Based on these results, Praxis plans a Phase III POWER2 study, alongside the ongoing pivotal POWER1 trial, with data expected Q4 2025.

If approved, GlobalData projects $456m in 2031 sales. Existing treatments, such as SK Biopharmaceuticals’ Xcorpi (cenobamate) and Eisai’s Fycompa (perampanel), are effective but leave 20–40% of focal epilepsy patients uncontrolled. This underscores the need for new first-line options. Full RADIANT results will be presented at the 36th International Epilepsy Congress in August and the American Epilepsy Society Meeting in December 2025.

10-08-2025